{
  "ticker": "LLY",
  "target_date": "2025-10-14",
  "actual_date": "2025-10-14",
  "collected_at": "2025-12-08T12:24:15.370138",
  "price": {
    "open": 820.88,
    "high": 820.88,
    "low": 804.82,
    "close": 811.15869140625,
    "volume": 1928400,
    "change_1d_pct": -0.86,
    "change_7d_pct": -3.28,
    "change_30d_pct": 10.5
  },
  "technicals": {
    "rsi_14": 65.67,
    "sma_20": 788.22,
    "sma_50": 743.81,
    "macd": 24.782,
    "macd_signal": 22.792,
    "macd_histogram": 1.99,
    "bb_upper": 884.72,
    "bb_lower": 691.72,
    "price_vs_sma20_pct": 2.91,
    "price_vs_sma50_pct": 9.05,
    "volume_ratio": 0.49
  },
  "fundamentals": {
    "market_cap": 894152867840,
    "pe_ratio": 48.86967,
    "forward_pe": 44.017212,
    "price_to_book": 37.55384,
    "price_to_sales": 15.048062,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.3,
    "pct_from_52w_low": 59.9
  },
  "macro": {
    "spy": {
      "price": 662.23,
      "change_1d_pct": -0.12,
      "change_7d_pct": -1.4
    },
    "vix": {
      "level": 20.81,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.02
    },
    "dollar_index": {
      "level": 99.05
    },
    "gold": {
      "price": 4138.7
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline",
      "source": "SeekingAlpha",
      "datetime": 1760459078,
      "summary": "BeOne Medicines AG earns Strong Buy rating as BRUKINSA drives growth and pipeline advances. Click here to find out why ONC stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=1d0a10d7b2e0517437c35b3be268caa7f050c7759cf82bca9da541ff8ce92d5d"
    },
    {
      "headline": "Kailera nets $600m to power Phase III launch of obesity drug",
      "source": "Yahoo",
      "datetime": 1760457743,
      "summary": "Weight loss treatment-focused biotechs are bucking the wider downturn in early-stage investments.",
      "url": "https://finnhub.io/api/news?id=6c206f0365765873436dfb71843d2f65cb738f7fa29de03ee82a3c5c70586ea4"
    },
    {
      "headline": "Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?",
      "source": "Yahoo",
      "datetime": 1760454540,
      "summary": "ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.",
      "url": "https://finnhub.io/api/news?id=6a8b7af46b3d6cfb0ab5527d9dc920b0d4a2f26f7e6667e176ab5929df99e608"
    },
    {
      "headline": "Kailera nets $600M more to advance Zepbound-like obesity drug",
      "source": "Yahoo",
      "datetime": 1760442300,
      "summary": "Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China.",
      "url": "https://finnhub.io/api/news?id=8f4deef4a4afd6bcde327836d0aa738c9a90eaac637cb12d2689ccc9d6aadd64"
    },
    {
      "headline": "The Zacks Analyst Blog Highlights Apple, Eli Lilly and Visa",
      "source": "Yahoo",
      "datetime": 1760431080,
      "summary": "Strong sector performers stand out as AAPL, LLY, and V gain traction through services, drug demand, and digital payment growth.",
      "url": "https://finnhub.io/api/news?id=3dd10953ee6e8fb9fa318e9bee8c356c437da1c6ea99c976645273dee63d2437"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-10-14",
      "description": "xslF345X05/form4-10142025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000037/xslF345X05/form4-10142025_041001.xml"
    },
    {
      "form": "4",
      "date": "2025-10-10",
      "description": "xslF345X05/form4-10102025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000035/xslF345X05/form4-10102025_041001.xml"
    },
    {
      "form": "4",
      "date": "2025-10-09",
      "description": "xslF345X05/form4-10092025_041002.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000031/xslF345X05/form4-10092025_041002.xml"
    },
    {
      "form": "4",
      "date": "2025-10-08",
      "description": "xslF345X05/form4-10082025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000029/xslF345X05/form4-10082025_041001.xml"
    },
    {
      "form": "4",
      "date": "2025-10-07",
      "description": "xslF345X05/form4-10072025_041001.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000027/xslF345X05/form4-10072025_041001.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}